Compare Johnson & Johnson (JNJ) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

USIG trades at $50.26, up 0.16% on the day, with a bearish technical signal from moving averages. Recent corporate actions include dividend payments, with the latest being $0.21 per share. The company's subsidiaries maintained credit ratings following a transaction with Tiptree Inc., as noted by AM Best on July 30, 2026.

The outlook is mixed, with technical indicators signaling caution, but institutional interest is present, as Bank of New York Mellon Corp increased its stake. Key risks include market volatility and execution of corporate strategies. The stock presents opportunities for income-focused investors due to dividends, but requires monitoring of fundamental developments.